Improve Gewinnerwartungen Quarterly and Anniversary Prognosis at Investing.com

On By Karl

NEW YORK – Der Biotechnologie-Riese Amgen (NASDAQ:) was written by Quartal Ergebnisse über den Analystenerwartungen gemeldet to achieve a strong Wachstum der Produktverkäufe in a Portfolio. The following is the Prognosis for Gesamtjahr 2024.

We made some gains with a higher analysis of $5.58 to $5.11 and $0.47. $8.5 Billion was left behind in the quarter, after $8.51 Billion there was a 23% increase in Vorjahr.

The product increased by 24%, with a volume increase of 29%, with a net increase of 2%. Unternehmens Horizon Therapeutics is one of the best kürzlich services with a production rate of 8%, including 12% in volume.

“Das starke Wachstum caused Umsatz and Gewinn to spread more widely than Schwung,” says Robert A. Bradway, Vorstandsvorsitzender and CEO of Amgen.

These products come in a range of four which includes Repatha, TEZSPIRE and BLINCYTO. Portfolio for Krankheiten is much larger than for Horizon-Übernahme, up to 1.2 Billion USD for Umsatz.

Mit Blick has teamed up to make a prediction for the 2024 Gesamtjahr. This resulted in an estimate of between $33.0 Billion and $33.8 Billion, which is an estimated estimate. By placing a trade of $19.20 and $20.00, you made some gains with analysis consensuses of $19.51.

This generated $3.3B in free Cash Flow in the Quarter and $2.5B in cash flow to efficiently generate a return on Working Capital.

Diese Übersetzung wurde mithilfe künstlicher Intelligenz erstellt. Learn more about the required information.